Idenix Pharmaceuticals, Inc.

• 3 Small Biotechs Top Hedge Funds Are Investing In

  By Shas Dey - April 23, 2013 | Tickers: ACOR, ALNY, IDIX

  Small biotech companies have great investment potential if you can identify them properly. A small biotech with a differentiated treatment approach and strong commercialization plans can become a rainmaker. However, given the level of cutting edge technology they use, a layperson without an MD or an advanced degree in statistics can hardly get a grip on these companies and what they are all about. Unless you know just how good more »

• Should You Sell These Biotechnology Stocks

  By Mohsin Saeed - April 14, 2013 | Tickers: CBM, DNDN, IDIX

  Bio-pharmaceutical companies usually make for some very high risk investments. This is because there are a number of factors that cannot be predicted accurately.The valuations skyrocket on drug approvals, but the actual performance in the market is an entirely different story. The following three stock have seen heavy institutional selling in the last few months, and I believe investors should stay away from them for the time. 

  Cambrex Corporation more »

• Hepatitis C In Play for 2013?

  By Terry Chrisomalis - February 25, 2013 | Tickers: ACHN, BMY, IDIX, VRTX

  In the world of biotech stocks a lot of companies are starting to incorporate Hepatitis C treatments into their pipelines. Hepatitis C is starting to garner a lot of attention, and these biotech companies are not wrong to be chasing this target disease. Why, you ask? Because there are currently 170 million people worldwide infected with Hep C, and this could mean huge opportunity for biotech companies that are in more »

• The Most Important New Drug of 2012

  By Jordo Bivona - January 9, 2013 | Tickers: ACHN, GILD, IDIX, VRTX

  Forbes recently crowned Vertex Pharmaceuticals' (NASDAQ: VRTX) Kalydeco the most important new drug of 2012. Forbes said that Kalydeco, used to treat cystic fibrosis, is a triumph of genetics and drug development and the first treatment to directly address the genetic defect that causes the disease.

  Kalydeco will only help 4 percent of the 70,000 people who suffer from declining lung function, a damaged pancreas, and shortened lives due more »

• Invest in the Great Progress of Hepatitis C

  By Streetwise Reports - December 8, 2012 | Tickers: ACHN, GILD, IDIX, JNJ

  By George S. Mack of The Life Sciences Report.

  For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.

  There are a lot of drug candidates in company pipelines for hepatitis C (HCV). In fact, your head could spin as you recite the product code number and letter combinations. I spoke with Sagient Research Analyst John Tucker who had just gotten back more »

• Is Bain Capital Betting Against Mitt Romney?

  By Meena Krishnamsetty - October 10, 2012 | Tickers: AMRN, IDIX, MAPP, PFE, VRTX

  As debate season heats up, we had an interesting takeaway from the first 2012 Presidential debate. Obama failed to mention anything about Romney’s old firm, Bain Capital. That is not going to stop us from mentioning it—in the issues that Romney and Obama did discuss, Romney continued to take the hardline that he would repeal Obamacare if elected.

  As mentioned, the fact that Obama failed to discuss anything more »

• Billionaire Seth Klarman’s Favorite Healthcare Stocks

  By Meena Krishnamsetty - August 27, 2012 | Tickers: AVEO, IDIX, THRX

  The Baupost Group, managed by value investor Seth Klarman (author of Margin of Safety), is one of the largest hedge funds in the world. It invests in a range of industries, but in the fund’s 13F filing for the second quarter of 2012 we noticed a number of healthcare companies in prime positions in its portfolio (see other stocks the Baupost Group owns). It can be difficult to evaluate more »

• Why Bristol-Myers is a Screaming Buy

  By Douglas Ehrman - August 22, 2012 | Tickers: BMY, GSK, IDIX, MRK, TEVA

  It is not often that an investment opportunity presents itself such that one wonders if the rest of the investing world has simply fallen asleep, but Bristol-Myers Squibb (NYSE: BMY) seems to be just such a case. The stock was seriously punished for pulling its hepatitis C drug from phase II trials, but a few months ago, the market yawned as the company announced positive results that will likely serve more »

• Is this biotech stock good for the long term?

  By Kevin Gill - August 22, 2012 | Tickers: GILD, IDIX, JNJ, MRK, VRTX

  In the race to make the best drug for treating Hepatitis C four biotech companies have shown real promise. Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), Merck (NYSE: MRK), Gilead Sciences (NASDAQ: GILD) and Vertex Pharmaceuticals (NASDAQ: VRTX). Each of these companies are looking to do the classic biotech stock move (that investors love) by popping the valuation of its stock with an exciting new product. But some of these companies have more »

• Bio Buyouts

  By AnnaLisa Kraft - July 28, 2012 | Tickers: ALXN, BMRN, IDIX, REGN, VRTX

  For biotech investors a positive phase III clinical trial is like a home run, an FDA approval is like a game winning grand slam but a buyout is like winning the World Series with fireworks, rainbows and unicorns. (OK, not unicorns). A buyout is what every biotech investor dreams of and over this last year there have been some monster buyouts.

  Biotech is usually about binary events like FDA approvals more »

• Former Drug Developer Discovers Next-Generation Biotech Stocks

  By Streetwise Reports - June 22, 2012 | Tickers: ACHN, ACOR, AMRN, IDIX, MDVN

  Former Drug Developer Discovers Next-Generation Biotech Stocks

  By George S. Mack, The Life Sciences Report

  Management is the key ingredient

  Raghuram "Ram" Selvaraju, an analyst I recently interviewed for The Life Sciences Report, began his initial career in translational drug discovery at Serono in 2000 with early and remarkable success. As a young researcher he demonstrated real insight and ability when he discovered the first novel protein candidate ever developed more »

• Keryx and Peers are Strong Buys

  By Jordo Bivona - May 28, 2012 | Tickers: ARNA, DNDN, IDIX, KERX, SPPI

  There is no shame in wanting to find cheap investments that pay off in the long run. The trouble is it can be tough to tell what is worth your money and what is cheap simply because it is worthless.

  Some are struggling companies that might never recover and I would encourage you to avoid the temptation of a low price. In other cases the prices are low, but the more »

• Why Idenix is a Good Bet for Aggressive Investors

  By Jordo Bivona - May 23, 2012 | Tickers: BMY, GILD, IDIX, VRTX

  We hear about life-threatening diseases almost every day. We hear about the serious illnesses caused by hepatitis and HIV viruses. Unfortunately, infections from these blood borne pathogens are one of the world's leading causes of death, which creates a serious global health problem.

  Hepatitis, the inflammatory swelling of the liver, may lead to cirrhosis or to cancer. There are three types, each one named for the virus causing it more »

• Idenix Will Sink Without Drug Success, Partnership

  By Maxwell Fisher - April 16, 2012 | Tickers: BMY, GILD, IDIX

  I don’t expect anything positive from Idenix Pharmaceuticals (NASDAQ: IDIX) this year. If you have money invested in its stock, I think it is time to cut the losses and get out because there will not be a turnaround anytime soon. Idenix has been developing drugs for hepatitis virus B and C. The frontrunner of its pipeline is a hepatitis C drug IDX184. The results of the most recent more »

• Why Idenix Pharmaceuticals Could Dive Further

  By Bobby Fisher - April 12, 2012 | Tickers: ABT, BMY, GILD, IDIX

  Currently, there are several pharmaceutical companies working on drug treatments for those with Hepatitis C. Among them is Idenix Pharmaceuticals (NASDAQ: IDIX). Its experimental drug, IDX 184, has undergone several preliminary tests over the past few months. The results have been less than stellar, however. Even though the drug helped fight the Hep C virus initially, patient relapse rates (usually within 12 weeks) could deter the drug from entering the more »

• Spectrum Pharmaceuticals: High Potential, Despite Failures

  By Bobby Fisher - April 10, 2012 | Tickers: ABT, IDIX, SNY, SPPI

  Anti-cancer treatments have become big business for biotech and pharmaceutical companies in recent years. Many companies have developed treatments for lesser known cancers in addition to introducing treatments for well-known cancers such as prostate, lung and breast cancer. But before a drug treatment enters the market, it must pass a series of clinical trials in order to receive approval from the FDA or other public safety agencies in Europe and more »

• Big Pharma's Newest Interest

  By Streetwise Reports - February 17, 2012 | Tickers: BMY, GILD, IDIX, INHX, MRK, VRTX

  Not even 15 years ago Hepatitis C virus (HCV) was thought to infect a bit more than 50 million people worldwide, but today health care demographers estimate the number to be between 130–170 million. In 2008, the U.S. Centers for Disease Control estimated 4 million people live with HCV in the U.S. Because the disease can be silent for a long time, there is a good chance more »

• There’s no Stopping Gilead Sciences

  By Amanda Alix - February 5, 2012 | Tickers: GILD, IDIX

  Gilead Sciences (NASDAQ: GILD) is on a roll.  The biotechnology firm has seen its profile rise along with its stock as every week, it seems, it has some new development to report.  The company is a leader in the antiviral market, leaving big players like Roche, Merck and Bristol-Meyers Squibb trailing in their wake.  Known best for their research and development of HIV drugs, their stock is currently surging on more »